中国临床药理学与治疗学2025，Vol.30Issue(2)：193-199,7.DOI:10.12092/j.issn.1009-2501.2025.02.005
抗血管生成靶向药物在治疗结直肠癌的耐药机制研究进展
Research progress on the resistance mechanism of anti-angiogenesis targeted drugs in the treatment of colorectal cancer
摘要
Abstract
Colorectal cancer(CRC)is one of the most common malignancies worldwide,although anti-angiogenic targeted agents such as bevacizum-ab have shown significant efficacy in the treatment of metastatic CRC,however,the emergence of drug resistance is still a key obstacle affecting the suc-cess rate of treatment and survival of patients.This article reviews the progress of anti-angiogenesis targeted drugs in the treatment of CRC,the mecha-nism of drug resistance and how to solve the prob-lem of drug resistance.关键词
结直肠癌/抗血管生成/耐药机制/靶向治疗Key words
colorectal cancer/anti-angiogenesis/mechanism of drug resistance/targeted therapy分类
临床医学引用本文复制引用
蒋海涛,许阳贤..抗血管生成靶向药物在治疗结直肠癌的耐药机制研究进展[J].中国临床药理学与治疗学,2025,30(2):193-199,7.基金项目
上海市自然科学基金面上项目(22ZR1462000) （22ZR1462000）
上海中医药大学附属龙华医院第四批龙医学者(Y21021) （Y21021）
上海市中医肿瘤临床医学中心(21MC1930500) （21MC1930500）
